IBDEI0GY ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7573,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7573,1,3,0)
 ;;=3^Urinary Retention,Unspec
 ;;^UTILITY(U,$J,358.3,7573,1,4,0)
 ;;=4^R33.8
 ;;^UTILITY(U,$J,358.3,7573,2)
 ;;=^5019331
 ;;^UTILITY(U,$J,358.3,7574,0)
 ;;=R39.15^^52^506^23
 ;;^UTILITY(U,$J,358.3,7574,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7574,1,3,0)
 ;;=3^Urinary Urgency
 ;;^UTILITY(U,$J,358.3,7574,1,4,0)
 ;;=4^R39.15
 ;;^UTILITY(U,$J,358.3,7574,2)
 ;;=^5019345
 ;;^UTILITY(U,$J,358.3,7575,0)
 ;;=R39.12^^52^506^24
 ;;^UTILITY(U,$J,358.3,7575,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7575,1,3,0)
 ;;=3^Weak Urinary Stream
 ;;^UTILITY(U,$J,358.3,7575,1,4,0)
 ;;=4^R39.12
 ;;^UTILITY(U,$J,358.3,7575,2)
 ;;=^5019342
 ;;^UTILITY(U,$J,358.3,7576,0)
 ;;=D51.8^^52^507^2
 ;;^UTILITY(U,$J,358.3,7576,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7576,1,3,0)
 ;;=3^Anemia,Vitamin B12 Deficiency
 ;;^UTILITY(U,$J,358.3,7576,1,4,0)
 ;;=4^D51.8
 ;;^UTILITY(U,$J,358.3,7576,2)
 ;;=^5002288
 ;;^UTILITY(U,$J,358.3,7577,0)
 ;;=D52.9^^52^507^1
 ;;^UTILITY(U,$J,358.3,7577,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7577,1,3,0)
 ;;=3^Anemia,Folate Deficiency
 ;;^UTILITY(U,$J,358.3,7577,1,4,0)
 ;;=4^D52.9
 ;;^UTILITY(U,$J,358.3,7577,2)
 ;;=^5002293
 ;;^UTILITY(U,$J,358.3,7578,0)
 ;;=I10.^^52^508^12
 ;;^UTILITY(U,$J,358.3,7578,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7578,1,3,0)
 ;;=3^Hypertension,Essential
 ;;^UTILITY(U,$J,358.3,7578,1,4,0)
 ;;=4^I10.
 ;;^UTILITY(U,$J,358.3,7578,2)
 ;;=^5007062
 ;;^UTILITY(U,$J,358.3,7579,0)
 ;;=I15.0^^52^508^13
 ;;^UTILITY(U,$J,358.3,7579,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7579,1,3,0)
 ;;=3^Hypertension,Renovascular
 ;;^UTILITY(U,$J,358.3,7579,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,7579,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,7580,0)
 ;;=I13.11^^52^508^8
 ;;^UTILITY(U,$J,358.3,7580,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7580,1,3,0)
 ;;=3^HTN Hrt & CKD w/o Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,7580,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,7580,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,7581,0)
 ;;=I13.2^^52^508^7
 ;;^UTILITY(U,$J,358.3,7581,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7581,1,3,0)
 ;;=3^HTN Hrt & CKD w/ Hrt Failure w/ Stage 5 Chr Kidney/ESRD
 ;;^UTILITY(U,$J,358.3,7581,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,7581,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,7582,0)
 ;;=I70.1^^52^508^3
 ;;^UTILITY(U,$J,358.3,7582,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7582,1,3,0)
 ;;=3^Atherosclerosis of Renal Artery
 ;;^UTILITY(U,$J,358.3,7582,1,4,0)
 ;;=4^I70.1
 ;;^UTILITY(U,$J,358.3,7582,2)
 ;;=^269760
 ;;^UTILITY(U,$J,358.3,7583,0)
 ;;=I77.3^^52^508^2
 ;;^UTILITY(U,$J,358.3,7583,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7583,1,3,0)
 ;;=3^Arterial Fibromuscular Dysplasia
 ;;^UTILITY(U,$J,358.3,7583,1,4,0)
 ;;=4^I77.3
 ;;^UTILITY(U,$J,358.3,7583,2)
 ;;=^5007812
 ;;^UTILITY(U,$J,358.3,7584,0)
 ;;=E26.02^^52^508^5
 ;;^UTILITY(U,$J,358.3,7584,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7584,1,3,0)
 ;;=3^Glucocorticoid-Remediable Aldosteronism
 ;;^UTILITY(U,$J,358.3,7584,1,4,0)
 ;;=4^E26.02
 ;;^UTILITY(U,$J,358.3,7584,2)
 ;;=^329904
 ;;^UTILITY(U,$J,358.3,7585,0)
 ;;=I12.9^^52^508^14
 ;;^UTILITY(U,$J,358.3,7585,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7585,1,3,0)
 ;;=3^Hypertensive CKD Stage 1-4
 ;;^UTILITY(U,$J,358.3,7585,1,4,0)
 ;;=4^I12.9
 ;;^UTILITY(U,$J,358.3,7585,2)
 ;;=^5007066
 ;;^UTILITY(U,$J,358.3,7586,0)
 ;;=I12.0^^52^508^15
 ;;^UTILITY(U,$J,358.3,7586,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7586,1,3,0)
 ;;=3^Hypertensive CKD Stage 5 or ESRD
